Not Yet RecruitingEarly Phase 1

The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

China10 participantsStarted 2025-04-01

Plain-language summary

Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
✓. Age: 18-75 years old (including boundary values of 18 and 75);
✓. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity

Exclusion criteria

✕. Individuals who have previously received bevacizumab
✕. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
✕. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;

What they're measuring

Negative conversion rate of evaluable residual lesions (MRD)

Timeframe: 1 year

Trial details

NCT IDNCT06876701

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-04-01

Contact for this trial

Wang Chun

13386259777 Zbruce.zhang@hotmail.com

View on ClinicalTrials.gov More Acute Leukemia trials